Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.59 |
| ▸ | NPC1 | O15118 | 8/20 | 0.59 |
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | GRM5 | P41594 | 1/20 | 0.59 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711545 | 1.00 | MEN1 (0.59) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL16915436 | 0.98 | MEN1 (0.57) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL16915438 | 0.98 | MEN1 (0.57) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4710534 | 0.82 | RAB9A (0.62) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4710535 | 0.82 | RAB9A (0.62) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4712658 | 0.81 | RAB9A (0.76) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4713161 | 0.80 | MEN1 (0.67) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4713319 | 0.80 | KMT2A (0.52) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4713317 | 0.80 | KMT2A (0.52) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4713163 | 0.80 | MEN1 (0.67) | MEN1KMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | claimed |
| US-9975860-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2018-05-22 | — | — | US | disclosed |
| EP-3094625-A1 | ANTI-ANGIOGENIC COMPOUNDS | University College Dublin National University Of Ireland, Dublin (IE) | 2016-11-23 | — | — | EP | disclosed |
| US-20160326122-A1 | Anti-Angiogenic Compounds | UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-11-10 | — | — | US | disclosed |
| WO-2015107122-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-07-23 | — | — | WO | disclosed |
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| CN-1203060-C | Pyridine derivatives, compositions and uses thereof | NOVARTIS AG (CH) | 2005-05-25 | — | — | CN | disclosed |
| US-6656957-B1 | Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. | NOVARTIS AG (CH) | 2003-12-02 | — | — | US | disclosed |
| CN-1262676-A | Pyridine derivatives | NOVARTIS AG (CH) | 2000-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326122-A1 | Anti-Angiogenic Compounds | VEGFA, FLT4, FLT1 | MEN1 3923/4885KMT2A 4855/4885NPC1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.